A nanoemulsion-adjuvanted trivalent neuraminidase vaccine confers cross-protection against divergent influenza viruses
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2026.1931757 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Jiaxin Bai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Changchun Institute of Biological Products Co., Ltd, Changchun, China. Hauptthemen laut MEDLINE: Neuraminidase, Influenza Vaccines, Orthomyxoviridae Infections, Cross Protection. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Technology of Jilin Province.
Abstract (Originalsprache)
Developing universal influenza vaccines (UIVs) capable of eliciting broad protection remains a critical public health priority. Neuraminidase (NA), a relatively conserved surface antigen of influenza viruses, is a promising target for UIV design. Here, we produced full-length trivalent NA proteins via a baculovirus-insect cell expression system, matching the WHO-recommended strains (H1N1, H3N2, and B/Victoria) for the 2024–2025 season. Immunogenicity evaluation of N2NA (derived from H3N2) in mice demonstrated that nanoemulsion (NE) adjuvant significantly enhanced NA-inhibiting (NI) antibody titers, CD4 T cell responses, and the numbers of IL-2-, IL-4- and IFN-γ-secreting lymphocytes compared to the unadjuvanted vaccine. Monovalent N1 NA and BV NA with NE adjuvant similarly induced stronger NI antibody responses and antiviral protection. Furthermore, the NE-adjuvanted trivalent NA vaccine (N1+N2+BV) elicited robust humoral and cellular immunity and provided effective protection in mice against two H1N1, two B/Victoria, and one H5N1 strain. Collectively, these findings support the efficacy of a multivalent NA-based vaccine strategy and highlight its strong potential as a candidate UIV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Changchun Institute of Biological Products Co., Ltd, Changchun, China.
- State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited, Beijing, China.
Förderung
- Department of Science and Technology of Jilin Province
Zitieren
APA
Bai, J., Li, S., Zhao, C., Yin, T., Li, D., Han, L., Qiao, Y., & Wu, Y. (2026). A nanoemulsion-adjuvanted trivalent neuraminidase vaccine confers cross-protection against divergent influenza viruses. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1931757
Vancouver
Bai J, Li S, Zhao C, Yin T, Li D, Han L, et al. A nanoemulsion-adjuvanted trivalent neuraminidase vaccine confers cross-protection against divergent influenza viruses. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1931757
BibTeX
@article{Bai2026,
author = {Bai, Jiaxin and Li, Shuang and Zhao, Chen and Yin, Ting and Li, Diansong and Han, Lirui and Qiao, Yongbo and Wu, Yehong},
title = {A nanoemulsion-adjuvanted trivalent neuraminidase vaccine confers cross-protection against divergent influenza viruses},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2026.1931757}
}
EUVIMED